Effects of CYP3A4*1G and CYP3A5*3 polymorphisms on pharmacokinetics of tylerdipine hydrochloride in healthy Chinese subjects

References

• Agrawal V, Choi JH, Giacomini KM, et al. (2010). Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase. Pharmacogenet Genomics 20:611–18.
   PubMed Web of Science ®Google Scholar
• Ball CJ, Wilson DP, Turner SP, et al. (2009). Heterogeneity of L- and T-channels in the vasculature: rationale for the efficacy of combined L- and T-blockade. Hypertension 53:654–60.
   PubMed Web of Science ®Google Scholar
• Daly AK. (2006). Significance of the minor cytochrome P450 3A isoforms. Clin Pharmacokinet 45:13–31.
   PubMed Web of Science ®Google Scholar
• Evans WE, McLeod HL. (2003). Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 348:538–49.
   PubMed Web of Science ®Google Scholar
• Gao Y, Zhang LR, Fu Q. (2008). CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin. Eur J Clin Pharmacol 64:877–82.
   PubMed Web of Science ®Google Scholar
• Guengerich FP. (1999). Cytochrome P-450 3A4: regulation and role in drug metabolism. Ann Rev Pharmacol Toxicol 39:1–17.
   PubMed Web of Science ®Google Scholar
• Hansen PB. (2015). Functional importance of T-type voltage-gated calcium channels in the cardiovascular and renal system: news from the world of knockout mice. Am J Physiol Reg Integ Comp Physiol 308:R227–37.
   PubMed Web of Science ®Google Scholar
• Hayashi K, Wakino S, Sugano N, et al. (2007). Ca2+ channel subtypes and pharmacology in the kidney. Circul Res 100:342–53.
   PubMed Web of Science ®Google Scholar
• He BX, Shi L, Qiu J, et al. (2014). The effect of CYP3A4*1G allele on the pharmacokinetics of atorvastatin in Chinese Han patients with coronary heart disease. J Clin Pharmacol 54:462–7.
   PubMed Web of Science ®Google Scholar
• Hu YF, Tu JH, Tan ZR, et al. (2007). Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects. Xenobiotica; Fate Foreign Comp Biol Syst 37:315–27.
   PubMed Web of Science ®Google Scholar
• Hustert E, Haberl M, Burk O, et al. (2001). The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11:773–9.
   PubMedGoogle Scholar
• Koch I, Weil R, Wolbold R, et al. (2002). Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Disposit Biol Fate Chem 30:1108–14.
   PubMed Web of Science ®Google Scholar
• Kuehl P, Zhang J, Lin Y, et al. (2001). Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383–91.
   PubMed Web of Science ®Google Scholar
• Major TC, Dhamija S, Black N, et al. (2008). The T- and L-type calcium channel blocker (CCB) mibefradil attenuates leg edema induced by the L-type CCB nifedipine in the spontaneously hypertensive rat: a novel differentiating assay. J Pharmacol Exp Therap 325:723–31.
   PubMed Web of Science ®Google Scholar
• Miura M, Satoh S, Kagaya H, et al. (2011). Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients. Pharmacogenomics 12:977–84.
   PubMed Web of Science ®Google Scholar
• Ozdemir V, Kalow W, Tang BK, et al. (2000). Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10:373–88.
   PubMedGoogle Scholar
• Qiu H, Mathas M, Nestler S, et al. (2010). The unique complexity of the CYP3A4 upstream region suggests a nongenetic explanation of its expression variability. Pharmacogenet Genom 20:167–78.
   PubMed Web of Science ®Google Scholar
• Qiu XY, Jiao Z, Zhang M, et al. (2008). Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients. Eur J Clin Pharmacol 64:1069–84.
   PubMed Web of Science ®Google Scholar
• Thummel KE, Wilkinson GR. (1998). In vitro and in vivo drug interactions involving human CYP3A. Ann Rev Pharmacol Toxicol 38:389–430.
   PubMed Web of Science ®Google Scholar
• Werk AN, Cascorbi I. (2014). Functional gene variants of CYP3A4. Clin Pharmacol Therap 96:340–8.
   PubMed Web of Science ®Google Scholar
• Westlind-Johnsson A, Malmebo S, Johansson A, et al. (2003). Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Disposit: Biol Fate Chem 31:755–61.
   PubMed Web of Science ®Google Scholar
• Yuan R, Zhang X, Deng Q, et al. (2011). Impact of CYP3A4*1G polymorphism on metabolism of fentanyl in Chinese patients undergoing lower abdominal surgery. Clinica chimica acta; Int J Clin Chem 412:755–60.
   PubMed Web of Science ®Google Scholar
• Zanger UM, Schwab M. (2013). Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103–41.
   PubMed Web of Science ®Google Scholar
• Zeng Y, He YJ, He FY, et al. (2009). Effect of bifendate on the pharmacokinetics of cyclosporine in relation to the CYP3A4*18B genotype in healthy subjects. Acta Pharmacologica Sinica 30:478–84.
   PubMed Web of Science ®Google Scholar
• Zhang J, Dai Y, Liu ZH, et al. (2017). Effect of CYP3A4 and CYP3A5 genetic polymorphisms on the pharmacokinetics of Sirolimus in healthy Chinese volunteers. Ther Drug Monit 39:406–11.
   PubMed Web of Science ®Google Scholar
• Zhang W, Chang YZ, Kan QC, et al. (2010). CYP3A4*1G genetic polymorphism influences CYP3A activity and response to fentanyl in Chinese gynecologic patients. Eur J Clin Pharmacol 66:61–6.
   PubMed Web of Science ®Google Scholar
• Zuo XC, Ng CM, Barrett JS, et al. (2013). Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis. Pharmacogenet Genom 23:251–61.
   PubMed Web of Science ®Google Scholar